Clinical review: Use of vancomycin in haemodialysis patients

被引：59

作者：

Launay-Vacher V. ^{[1
]}

Izzedine H. ^{[1
]}

Mercadal L. ^{[1
]}

Deray G. ^{[1
]}

机构：

[1] Department of Nephrology, Pitie-Salpetriere Hospital, Paris

来源：

Critical Care | / 6卷 / 4期

关键词：

Haemodialysis; Vancomycin;

D O I：

10.1186/cc1516

中图分类号：

学科分类号：

摘要：

Following intravenous administration, vancomycin is poorly metabolized and is mainly excreted unchanged in urine. Total body clearance is thus dependent on the kidney, and is correlated with glomerular filtration rate and creatinine clearance. Accumulation of vancomycin in patients with renal insufficiency may therefore occur, and this may lead to toxic side effects if dosage is not modified according to the degree of renal failure. Furthermore, vancomycin easily diffuses through dialysis membranes. The aim of the present review is to establish guidelines for handling this drug in such patients. We indicate how and when plasma concentrations of vancomycin should be determined in dialysis patients.

引用

页码：313 / 316

页数：3

共 23 条

[1]

Moellering R.C. Jr., Krogstad D.J., Greenblatt D.J., Vancomycin therapy in patients with impaired renal function: A nomogram for dosage, Ann. Intern. Med, 94, pp. 343-346, (1981)

[2]

Dollery C., Vancomycin, Therapeutic Drugs, (1999)

[3]

Wysocki M., Delatour F., Faurisson F., Rauss A., Pean Y., Misset B., Thomas F., Timsit J.F., Similowski T., Mentec H., Mier L., Dreyfuss D., Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective multicenter randomized study, Antimicrob. Agents Chemother, 45, pp. 2460-2467, (2001)

[4]

Nielsen H.E., Hansen H.E., Korsager B., Skov P.E., Renal excretion of vancomycin in kidney disease, Acta Med. Scand, 197, pp. 261-264, (1975)

[5]

Matzke G.R., McGory R.W., Halstenson C.E., Keane W.F., Pharmacokinetics of vancomycin in patients with various degrees of renal function, Antimicrob. Agents Chemother, 25, pp. 433-437, (1984)

[6]

Macias W.L., Mueller B.A., Scarim S.K., Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance, Clin. Pharmacol. Ther, 50, pp. 688-694, (1991)

[7]

Lake K.D., Peterson C.D., A simplified dosing method for initiating vancomycin therapy, Pharmacotherapy, 5, pp. 640-644, (1985)

[8]

Andres I., Lopez R., Pou L., Pinol F., Pascual C., Vancomycin monitoring: One or two serum levels?, Ther. Drug Monit, 19, pp. 614-619, (1997)

[9]

Mulhern J.G., Braden G.L., O'Shea M.H., Madden R.L., Lipkowitz G.S., Germain M.J., Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients, Am. J. Kidney Dis, 25, pp. 611-615, (1995)

[10]

Bailie G.R., Neal D., Vancomycin ototoxicity and nephrotoxicity. A review, Med. Toxicol, 3, pp. 376-386, (1988)

← 1 2 3 →